Evaluating blood biomarkers in patients with asymptomatic carotid artery stenosis
The VANGAS-Trial. The Value of Neurofilament Light Chain and Glial Fibrillary Acid Protein in the Blood of Patients With Asymptomatic Carotid Artery Stenosis
Heinrich-Heine University, Duesseldorf · NCT06211725
This study is testing if certain blood markers can help identify older patients with narrowed carotid arteries who might be at risk for stroke and need further treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 60 Years to 80 Years |
| Sex | All |
| Sponsor | Heinrich-Heine University, Duesseldorf (other) |
| Locations | 2 sites (Düsseldorf, NRW and 1 other locations) |
| Trial ID | NCT06211725 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the value of neurofilament light chain and glial fibrillary acid protein as potential biomarkers in the blood of patients with asymptomatic carotid artery stenosis. The study focuses on understanding the risk factors associated with stroke in these patients and determining whether these biomarkers can help identify those who may require revascularization. By analyzing blood samples from participants aged 60 to 80 with varying degrees of stenosis, the study seeks to clarify the role of these biomarkers in stroke prevention.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 60 to 80 with asymptomatic carotid artery stenosis.
Not a fit: Patients with neurodegenerative diseases, recent strokes, or transient ischemic attacks may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved identification of patients at risk for stroke, allowing for timely interventions.
How similar studies have performed: While the use of blood biomarkers in stroke risk assessment is a growing field, this specific approach is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 60- 80 years * 0-100 % stenosis of the internal carotid artery Exclusion Criteria: * Neurodegenerative diseases such as any form of dementia or Parkinson\'s disease * Polyneuropathy * Multiple sclerosis * Stroke (ischaemic or haemorrhagic) within the last 12 months * Transient ischaemic attack within the last 12 months * Neurotrauma within the last 12 months * Atrial fibrillation
Where this trial is running
Düsseldorf, NRW and 1 other locations
- University hospital Düsseldorf — Düsseldorf, NRW, Germany (RECRUITING)
- Kliniken Maria Hilf GmbH — Mönchengladbach, NRW, Germany (RECRUITING)
Study contacts
- Study coordinator: Michael / John-Ih / MG Gliem / Lee, MD
- Email: michael.gliem@med.uni-duesseldorf.de
- Phone: +49174 - 271 57 39
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Carotid Artery Stenosis, Carotid Artery Stenosis Asymptomatic, Carotid Artery Diseases, Carotid Artery Plaque, Carotid Artery Disease, Carotid Artery Stenosis asymptomatic, Carotid artery stenosis biomarker, carotid artery nfl